Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Myelodysplastic Syndromes 19Lymphoma, Non-Hodgkin 17Leukemia, Lymphocytic, Chronic, B-Cell 15Hodgkin Disease 15Graft vs Host Disease 13Lymphoma, Mantle-Cell 12Leukemia 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 11Sarcoma 10Lymphoma 10Lymphoma, Follicular 9Lymphoma, B-Cell, Marginal Zone 9Burkitt Lymphoma 9Myeloproliferative Disorders 8Waldenstrom Macroglobulinemia 7Tuberous Sclerosis 7Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Hematologic Neoplasms 7Congenital Abnormalities 7Primary Myelofibrosis 6Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myeloid, Accelerated Phase 6Breast Neoplasms 6Osteosarcoma 5

Interventions

Octreotide 4Everolimus 4Capecitabine 3Temozolomide 2Melphalan 2Biological Therapy 2vatalanib 1temsirolimus 1romidepsin 1regorafenib 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Leucovorin 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Fluorouracil 1Filgrastim 1Cytokines 1Complementary Therapies 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Islet Cell × Sirolimus × Clear all
NCT00093782 2017-02-07

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 12 charts

Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡